San Diego, California — September 24, 2010. Solulink, Inc., a leading innovator of state-of-
the-art conjugation reagents, easy-to-use linking kits, and conjugation services for the life
science research, diagnostics, and pharmaceutical markets, today announced it has been
awarded approximately $150,000 for a National Cancer Institute (NCI) SBIR Contract to develop
a multiplex screen for simultaneous detection of multiple breast cancer markers. The grant
entitled, “Universal Reagent Sets for Sensitive and Specific Multiplexed Immunofluorescent
Cancer Diagnostics” proposes to develop an immunohistochemistry-based multiplex assay to
detect multiple breast cancer biomarkers in a single tissue sample. The assay will be
developed in association with Drs. Stephen Kron, Professor, Dept. Molecular Genetics and Cell
Biology and Anthony Montag, Professor of Pathology and Surgery, at the University of Chicago.
David Schwartz, Ph.D., Solulink’s Chief Science Officer and Principal Investigator for the project
stated, “We are pleased that SBIR has awarded us the opportunity to apply our state of the art
protein multiplexing platform technology to this important goal. With this grant, we propose to
use our proprietary technology in combination with nanotechnology, bioorganic chemistry,
immunochemistry, immunology and available instrumentation to develop an assay that provides
more rapid and more complete diagnostic information, thereby enabling oncologists to make
more informed decisions. We also are excited about continuing our collaboration with the
University of Chicago in exploiting our technology in multiple diagnostic platforms”
The Small Business Innovation Research Program (SBIR) works to ensure that the nation’s
small, high-tech, innovative businesses act as a significant part of the federal government’s
research and development projects. In reviewing grant applications, the SBIR seeks unique
research projects that are of high scientific caliber and are relevant to public health needs.
SBIR Grant number: PH3 2010-1 NCI Topic 274
About Solulink
Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features
and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to
a wide range of surfaces including beads, chips, and slides. Solulink has developed several
lines of products that incorporate its technology including streptavidin magnetic and agarose
beads that have the highest binging capacity on the market, ChromaLink Biotin with a built in
quantification feature, antibody labeling kits, oligo and peptide synthesis reagents. Solulink
markets its products both directly and through distributors and licensing partners worldwide.
Solulink is a privately held company located in San Diego, California. For more information,
please visit www.solulink.com.
Contact
Steve DeGraw
Solulink, Incorporated
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121
T 858.625.0670
F 858.625.0770
sdegraw@solulink.com